Abstract:Objective To evaluate the efficacy and safety of telmisartan+hydrochlorothiazide(T-H) and telmisartan monotherapy(T-m) in patients with mild to moderate essential hypertension.Methods This was a multicenter,randomized,double-blind,double-dummy,comparative,controlled trial.After a 2-week,single-blind,placebo run-in period,patients with mild to modertate hypertension were eligible to enter the 4-week,single-blind treatment with telmisartan monotherapy.Next,if DBP < 90mmHg,the patients will be excluded;if 90 ≤ DBP < 110 mmHg,the patients will enter the 8-week,double-blind,double-dummy therapy period and according to the randomized principle,they were divided into two groups.Study comparisons were between once-daily telmisartan+hydrochlorothiazide and telmisartan monotherapy.The primary endpoint was the decline of DBP from week 4 to week 12.Blood biochemical examinations,ECG,ABPM,etc were the observational parameters,too.Results(1) In total,300 patients(eight hospitals) were enrolled in and 213 patients had completed the study.One severe adverse event—myocardial infarction—ccurred in a patient,but it was considerd drug independent.(2) When unblinded,it revealed that there was a significant significance in the decline of DBP(A(12.66±10.76)mmHg,B(7.89±12.15)mmHg,P=0.0203).(3) At week 12,both groups had a sharply drop of BP,but T-H provided significantly greater reductions than T-m(SBP:P=0.0016;DBP:P=0.0186).The total efficacy rate was higher in T-H group(T-H:83.1%;T-m:67.2%,P<0.05),and the BP target achievement rate(T-H:71.8%,T-m:54.9%,P=0.0061),as well.The T/P ratio was>50% in both groups.(4) There was no significant difference between the two groups in the rate of total adverse events(T-H:21.8%,T-m:22.1%,P=0.9461) and drug-dependent adverse events(T-H:8.1;T-m:9.8%.P=0.6264).Conclusions T-H and T-m can both significantly and steadily reduce SBP and DBP and are very safe,well tolerated and accepted by patients with mild to moderate essential hypertension.T-H provides significantly greater BP lowering than T-m.

Effects and safety of mild and moderate primary hypertension treated with olmesartan medoxomil tablet

Clinical Study of Olmesartan/hydrochlorothiazide Compound Tablet in Mild to Moderate Essential Hypertensive Patients Who Did Not Reach Goal with Olmesartan

Efficacy and Safety of Olmesartan Medoxomil in Patients with Mild to Moderate Essential Hypertension

[Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Chinese Patients with Mild to Moderate Essential Hypertension].

The Effects of Olmesartan on Ambulatory Blood Pressures and Blood Pressure Variability in Patients with Mild to Moderate Essential Hypertension

Efficacy and Safety of Domestic Olmesartan in Treatment of Mild to Moderate Essential Hypertension

Antihypertensive Efficacy and Safety of Domestic Olmesartan Monotherapy in Mild or Moderate Essential Hypertension

Efficacy and Safety of Olmesartan Medoxomil-Amlodipine Besylate Tablet in Chinese Patients with Essential Hypertension: A Prospective, Single-Arm, Multi-Center, Real-World Study

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

Reduction of the Morning Blood Pressure Surge Treated with Olmesartan in Chinese Patients with Mild to Moderate Essential Hypertension - A Multicenter, Open-Label, Single Treatment Group Clinical Study

Using Different Methods to Evaluate the Efficacy of Olmesartan Medoxomil in Chinese Patients with Mild to Moderate Essential Hypertension According to Ambulatory Blood Pressure Monitoring

The Clinical Efficacy and Safety of Valsartan in Treatment of Patients with Essential Hypertensive

Clinical efficacy and safety of telmisartan in patients with mild to moderate hypertension: a multi-center randomized controlled clinical trial

Efficacy of telmisartan/hydrochlorothiazide in patients with mild to moderate primary hypertension using ambulatory blood pressure monitoring

Long-Term Efficacy of Olmesartan Medoxomil in Chinese Hypertensive Patients As Assessed by Clinic, Ambulatory and Home Blood Pressure Measurements

The efficacy and safety of allisartan in patients with mild to moderate essential hypertension

Clinical effectiveness and safety of candesartan cilexetil in treatment of patients with mild and moderate essential hypertension

Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy

Efficacy and Safety of Olmesartan Medoxomil‑amlodipine Besylate Tablets (sevikar®) in Older Patients with Essential Hypertension: Subgroup Analysis from the Sevikar Study.

Clinical Observation on efficacy and safety of Telmisartan hydrochlorothiazide and Telmisartan in patients with Mild to Moderate Essential hypertension

Comparison of eprosartan and losartan in patients with mild to moderate essential hypertension